Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
about
Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell functionProfile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesProtein biomarkers of mood disorders.The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.Chronic Vortioxetine Treatment Reduces Exaggerated Expression of Conditioned Fear Memory and Restores Active Coping Behavior in Chronically Stressed RatsThe serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus.Vortioxetine: a New Treatment for Major Depressive Disorder.Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release.Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters.Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine.Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men.A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trialsA Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive DisorderLack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium.The serotonergic system and cognitive functionThe Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.New drugs in psychiatry: focus on new pharmacological targets.A randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission.Response of Htr3a knockout mice to antidepressant treatment and chronic stress.Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action' (Hjorth et al., 2000).Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition.The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.Vortioxetine: A Review in Cognitive Dysfunction in Depression.Structures and physicochemical properties of vortioxetine salts.Prefrontal cortex executive processes affected by stress in health and disease.Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats.Hippocampal 5-HT7 receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo.Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents.Z-Guggulsterone Produces Antidepressant-Like Effects in Mice through Activation of the BDNF Signaling Pathway.Laminar and Cellular Distribution of Monoamine Receptors in Rat Medial Prefrontal Cortex
P2860
Q26783101-1B800B7C-D029-49E3-86E6-57825F123299Q26796436-8D94E18B-5CB0-4757-9244-8D92AC884B78Q28066691-AD1F2691-F301-4BDE-944D-EFDC91F4DDE8Q30395834-29171DAC-7E60-4A15-B7DE-9687EE2A379FQ31044175-23E6EB60-947D-4D0C-B4E6-13D09B2DD791Q33614804-50753FCE-7CF6-4DC3-BC5D-08BBBC52CF0DQ34497909-92DB779B-DD55-40F1-A397-5DDB7A7814F1Q34505291-A7A59807-B5CE-4330-9259-DA645CFAD2A8Q34505568-6742E7AC-6D25-4EDD-BB28-60DB703304EEQ34670552-FB57CD9A-4240-4975-BAF0-3F5E455C5F2DQ34670569-DCD4C221-59CB-4EBD-858D-474A5491D74DQ34671039-CAD8FF96-3BA1-4752-BE03-46CA4FBDBA63Q34671692-7A6F93A8-1896-4D84-BD11-54E5C1CB5C53Q34672117-E109E21C-7648-4933-B741-38A360F08FDCQ35607556-A9C36975-C6BE-4024-B1F3-3D7594266CAFQ35862776-56449717-004D-4ECD-B360-15E0E9964B29Q36653073-CFB841A6-AC15-4255-9F38-2280EAFA473AQ36821817-13904CAE-CB54-4CF3-BAEA-70C6A15E1E3DQ37201637-7BF0BC0A-38A6-4BF7-BC58-841F7DEDA843Q37245282-9408BB4C-B022-492E-9025-75B1FBE3E445Q37388486-7CA4618A-06BF-41D2-A433-E2241495102EQ37694366-92563FA3-9A58-401A-A3AE-DE53E9689CB1Q37730207-FEC1521E-9CF2-49E4-AB3E-5B64477B0621Q38371388-A0C54C44-EF64-4798-A55D-DFB208FAD979Q38439748-198AB1E5-2613-439B-944E-F577EE1AD287Q38506798-9014B931-4335-4696-BB61-DFB7B22FEBADQ38543238-0D51DAAF-5E30-448C-BE74-61C2057E934CQ38562129-F8289A64-BC78-4DA5-B0DC-19138AA4C418Q38792343-E4452A0E-0738-4220-81F0-853697459FC4Q38868838-221F68F3-FBC8-40E6-B0AA-44AFAAD903EAQ38897362-9AAD8545-E4FE-4CCF-9DC9-9D263EEDC94CQ38934855-C261637E-8B10-42E4-8283-BAA2CBB9BB85Q38997216-837F0E96-DA9C-498F-8EA5-69EDE11DAD64Q39326667-8EFA8D82-0FC6-482A-94AE-844357A291DEQ39424256-3AE7DFB9-2AC1-4291-8265-C9320D9175DBQ39612025-726C885C-DFB0-4124-8922-238B37BC88DFQ40160363-4AE000E2-E25B-46DA-8477-EE28211DDD85Q41250682-8E5AAB13-37A5-4575-A847-443BEF46979EQ41989346-69A0B475-3826-45F4-B768-672F2A8DFF7BQ42369139-E135DBC3-5F54-41B0-8A74-BE313BB857A5
P2860
Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Vortioxetine, a novel antidepr ...... preclinical and clinical data.
@ast
Vortioxetine, a novel antidepr ...... preclinical and clinical data.
@en
type
label
Vortioxetine, a novel antidepr ...... preclinical and clinical data.
@ast
Vortioxetine, a novel antidepr ...... preclinical and clinical data.
@en
prefLabel
Vortioxetine, a novel antidepr ...... preclinical and clinical data.
@ast
Vortioxetine, a novel antidepr ...... preclinical and clinical data.
@en
P2093
P1476
Vortioxetine, a novel antidepr ...... preclinical and clinical data.
@en
P2093
Connie Sanchez
Francesc Artigas
Karen E Asin
P356
10.1016/J.PHARMTHERA.2014.07.001
P577
2014-07-09T00:00:00Z